지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2024.4
- 수록면
- 987 - 1,000 (14page)
- DOI
- 10.1038/s12276-024-01210-5
이용수
초록· 키워드
오류제보하기
Transcriptional programs governed by YAP play key roles in conferring resistance to various molecular-targeted anticancer agents. Strategies aimed at inhibiting YAP activity have garnered substantial interest as a means to overcome drug resistance. However, despite extensive research into the canonical Hippo–YAP pathway, few clinical agents are currently available to counteract YAP-associated drug resistance. Here, we present a novel mechanism of YAP stability regulation by MAP3K3 that is independent of Hippo kinases. Furthermore, we identified MAP3K3 as a target for overcoming anticancer drug resistance. Depletion of MAP3K3 led to a substantial reduction in the YAP protein level in melanoma and breast cancer cells. Mass spectrometry analysis revealed that MAP3K3 phosphorylates YAP at serine 405. This MAP3K3-mediated phosphorylation event hindered the binding of the E3 ubiquitin ligase FBXW7 to YAP, thereby preventing its p62-mediated lysosomal degradation. Robust YAP activation was observed in CDK4/6 inhibitor-resistant luminal breast cancer cells. Knockdown or pharmacological inhibition of MAP3K3 effectively suppressed YAP activity and restored CDK4/6 inhibitor sensitivity. Similarly, elevated MAP3K3 expression supported the prosurvival activity of YAP in BRAF inhibitor-resistant melanoma cells. Inhibition of MAP3K3 decreased YAP-dependent cell proliferation and successfully restored BRAF inhibitor sensitivity. In conclusion, our study reveals a previously unrecognized mechanism for the regulation of YAP stability, suggesting MAP3K3 inhibition as a promising strategy for overcoming resistance to CDK4/6 and BRAF inhibitors in cancer treatment.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Clinical implications of the Hippo-YAP pathway in multiple cancer contexts
BMB Reports
2018 .01
-
DNA binding partners of YAP/TAZ
BMB Reports
2018 .01
-
The potential role of YAP in head and neck squamous cell carcinoma
Experimental and Molecular Medicine
2020 .08
-
Roles of YAP in mediating endothelial cell junctional stability and vascular remodeling
BMB Reports
2015 .01
-
YAP inactivation in estrogen receptor alpha-positive hepatocellular carcinoma with less aggressive behavior
Experimental and Molecular Medicine
2021 .06
-
YAP1 inhibits the senescence of alveolar epithelial cells by targeting Prdx3 to alleviate pulmonary fibrosis
Experimental and Molecular Medicine
2024 .07
-
Dishevelling Wnt and Hippo
BMB Reports
2018 .01
-
Resveratrol suppresses breast cancer cell invasion by inactivating a RhoA/YAP signaling axis
Experimental and Molecular Medicine
2017 .01
-
Regulation of Hippo signaling by actin remodeling
BMB Reports
2018 .01
-
Hippo-YAP/TAZ signaling in angiogenesis
BMB Reports
2018 .01
-
Regulation and Regulators of the Hippo-YAP/TAZ Pathway
한국생물공학회 학술대회
2016 .10
-
Deubiquitinase YOD1: the potent activator of YAP in hepatomegaly and liver cancer
BMB Reports
2017 .06
-
Effect of PFKFB3 on YAP-TEAD Interaction
한국생물공학회 학술대회
2024 .09
-
Marine Sponge-Derived Spicule-Enhanced Injectable Hydrogel: Dual-Level Mechanochemical Regulation and YAP/TAZ Pathway Activation for Enhanced Bone Regeneration
한국생물공학회 학술대회
2024 .09
-
The Foxo1-YAP-Notch1 axis reprograms STING-mediated innate immunity in NASH progression
Experimental and Molecular Medicine
2024 .08
-
Insulin receptor substrate 2: a bridge between Hippo and AKT pathways
BMB Reports
2018 .01
-
Interacting network of Hippo, Wnt/β-catenin and Notch signaling represses liver tumor formation
BMB Reports
2017 .01
-
The role of extracellular biophysical cues in modulating the Hippo-YAP pathway
BMB Reports
2017 .01
-
USP15 promotes pulmonary vascular remodeling in pulmonary hypertension in a YAP1/TAZ-dependent manner
Experimental and Molecular Medicine
2023 .01
최근 본 자료
댓글(0)
0